Because
bladder cancer (BC) is one of the most common malignant
cancers of the urinary system, identification of BC cell growth-associated effectors is of great significance.
Cyclin-dependent kinase (CDK)6 is a member of the CDK family of cell cycle-related
proteins and plays an important role in
cancer cell growth. This is borne out by the fact that a CDK6 inhibitor had been approved to treat several types of
cancers. Nevertheless, underlying molecular mechanisms concerning how to regulate CDK6 expression in BC remains unclear. In the present study, it was observed that miR-934 was much higher in human BCs and human BC cell lines as well. The results also revealed that miR-934 inhibition dramatically decreased human BC cell monolayer growth in vitro and xenograft
tumor growth in vivo; the outcomes were accompanied by
CDK6 protein down-regulation and G0-G1 cell cycle arrest. Moreover, overexpression of CDK6 reversed the inhibition of BC cell growth induced by miR-934. Further studies showed that miR-934 binds to a 3'-UTR of
ubiquitin-conjugating enzyme 2N (ube2n)
mRNA, down-regulated UBE2N
protein expression; this, in turn, attenuated
CDK6 protein degradation and led to
CDK6 protein accumulation as well as the promotion of BC
tumor growth. Collectively, this study not only establishes a novel regulatory axis of miR-934/UBE2N of CDK6 but also provides data suggesting that miR-934 and UBE2N may be potentially promising targets for therapeutic strategies against BC.-Yan, H., Ren, S., Lin, Q., Yu, Y., Chen, C., Hua, X., Jin, H., Lu, Y., Zhang, H., Xie, Q., Huang, C., Huang, H. Inhibition of UBE2N-dependent
CDK6 protein degradation by miR-934 promotes human
bladder cancer cell growth.